Feeds

No Dr No rights for Bond owners

EU court does not find trade mark sufficiently suave

Boost IT visibility and business value

The company behind the James Bond film franchise cannot stop another company from registering 'Dr No' as a trade mark because the film title is an indication of artistic, and not commercial, origin, an EU court has said.

The Court of First Instance (CFI) in Brussels ruled on a trade mark dispute between Danjaq, the owner of the Bond franchise, and a company which had registered Dr No for goods such as bags, clothing, hats and drinks.

Mission Productions registered the trade mark in 2001 and it was opposed by Danjaq in 2002. The EU body that regulates Community Trade Marks OHIM (the Office for the Harmonisation of Internal Markets), rejected Danjaq's opposition. The case was appealed to the CFI.

Dr No, starring Sean Connery and Ursula Andress, was the first Bond film to be made, in 1962. There followed many other films featuring James Bond, and the series has become one of the most famous film franchises ever.

The case concerned two almost-identical marks, Dr No and Dr NO.

The CFI said that it first had to consider whether or not they had been used as trade marks before Mission Productions' application for registration. Danjaq said that it had used the term as a trade mark for many goods, and that they were well-known marks.

The Court said that the purpose of trade marks is to identify the commercial origin of goods to enable consumers to buy in confidence. It said that this is not what the Dr No marks did, and that their function was cultural rather than commercial.

"The signs Dr. No and Dr. NO do not indicate the commercial origin of the films, but rather their artistic origin," said the ruling. "For the average consumer, the signs in question, affixed to the covers of the video cassettes or to the DVDs, help to distinguish that film from other films in the ‘James Bond’ series."

"The commercial origin of the film is indicated by other signs, such as ‘007’ or ‘James Bond’, which are affixed to the covers of the video cassettes or to the DVDs, and which show that its commercial origin is the company producing the films in the ‘James Bond’ series," it said.

The Court also rejected Danjaq's claim about what its rights and entitlements to the name Dr No were.

"Contrary to the applicant’s claim, the distinction between title and trade mark is not ‘unrealistic and artificial’," said the ruling. "The same sign may be protected as an original creative work by copyright and as an indicator of commercial origin by trade mark law. It is therefore a matter of different exclusive rights based on distinct qualities, that is to say the original nature of a creation, on the one hand, and the ability of a sign to distinguish the commercial origin of the goods and services, on the other."

"Even if the title of a film can be protected pursuant to certain national laws as an artistic creation independent of the film itself, it cannot automatically enjoy the protection afforded to indicators of commercial origin, since only signs which develop characteristic trade mark functions may enjoy that protection," it said.

The court said that the fact that the name Dr No was used in relation to goods associated with the film did not automatically make that use trade mark use.

"In the case of comic books, music recordings, books and posters, the signs Dr. No and Dr. NO are likewise not used as trade marks, but as a reference which is descriptive of the goods, indicating to consumers that they are music from the film Dr. No, a book or a comic book about the character of ‘Dr. No’, or a poster of that film or character," it said.

"The applicant has failed to establish that the signs Dr. No and Dr. NO were used as trade marks prior to the date of application for registration of the Community trade mark," it said.

Because it had failed the first of the three legal hurdles put in front of it, Danjaq lost the case and the Court did not consider the issue further.

"Since it has not been established that the signs Dr. No and Dr. NO were used as indicators of commercial origin before the Community trade mark application was filed, they cannot be regarded as well-known trade marks," it said.

See: The ruling

Copyright © 2009, OUT-LAW.com

OUT-LAW.COM is part of international law firm Pinsent Masons.

Build a business case: developing custom apps

More from The Register

next story
Hello, police, El Reg here. Are we a bunch of terrorists now?
Do Brits risk arrest for watching beheading video nasty? We asked the fuzz
Snowden on NSA's MonsterMind TERROR: It may trigger cyberwar
Plus: Syria's internet going down? That was a US cock-up
UK government accused of hiding TRUTH about Universal Credit fiasco
'Reset rating keeps secrets on one-dole-to-rule-them-all plan', say MPs
Caught red-handed: UK cops, PCSOs, specials behaving badly… on social media
No Mr Fuzz, don't ask a crime victim to be your pal on Facebook
Felony charges? Harsh! Alleged Anon hackers plead guilty to misdemeanours
US judge questions harsh sentence sought by prosecutors
e-Borders fiasco: Brits stung for £224m after US IT giant sues UK govt
Defeat to Raytheon branded 'catastrophic result'
Yes, but what are your plans if a DRAGON attacks?
Local UK gov outs most ridiculous FoI requests...
EU justice chief blasts Google on 'right to be forgotten'
Don't pretend it's a freedom of speech issue – interim commish
This'll end well: US govt says car-to-car jibber-jabber will SAVE lives
Department of Transportation starts cogs turning for another wireless comms standard
Munich considers dumping Linux for ... GULP ... Windows!
Give a penguinista a hug, the Outlook's not good for open source's poster child
prev story

Whitepapers

Implementing global e-invoicing with guaranteed legal certainty
Explaining the role local tax compliance plays in successful supply chain management and e-business and how leading global brands are addressing this.
Top 10 endpoint backup mistakes
Avoid the ten endpoint backup mistakes to ensure that your critical corporate data is protected and end user productivity is improved.
Top 8 considerations to enable and simplify mobility
In this whitepaper learn how to successfully add mobile capabilities simply and cost effectively.
Rethinking backup and recovery in the modern data center
Combining intelligence, operational analytics, and automation to enable efficient, data-driven IT organizations using the HP ABR approach.
Reg Reader Research: SaaS based Email and Office Productivity Tools
Read this Reg reader report which provides advice and guidance for SMBs towards the use of SaaS based email and Office productivity tools.